[Special Stock] SillaJen Surges 18% on IND Approval for Solid Tumor Treatment Phase 1 in Korea

Shinilajen surged more than 18% after receiving approval from the Ministry of Food and Drug Safety for its domestic Phase 1 clinical trial plan (IND) related to solid cancer treatment.

As of 9:57 AM on the 14th, Shinilajen was trading at 6,980 KRW, up 18.51% from the previous day.

The day before, Shinilajen announced that the Ministry of Food and Drug Safety had approved the Phase 1 clinical trial plan for BAL0891 as a monotherapy and in combination with chemotherapy for patients with advanced solid tumors.